Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

doi:10.1016/s0959-8049(03)00026-1

Article

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

European journal of cancer (Oxford, England : 1990) - 1 Apr 2003

Burger H, den Bakker M A, Stoter G, Verweij J, Nooter K

Abstract excerpt

Previous studies have shown that STI571, a selective tyrosine kinase inhibitor of c-KIT, is highly effective in c-KIT/CD117-positive gastrointestinal stromal tumours (GIST), especially those that have activating mutations in the c-kit exon 11 that encodes the juxtamembrane (JM) domain of the c-KIT oncoprotein. We examined the prevalence of activating exon 11 c-kit mutations in 26 small-cell lung cancer (SCLC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

Abstract excerpt

Topics

Related research